Literature DB >> 19043703

Kinetic modelling of [11C]flumazenil using data-driven methods.

Isabelle Miederer1, Sibylle I Ziegler, Christoph Liedtke, Mary E Spilker, Matthias Miederer, Till Sprenger, Klaus J Wagner, Alexander Drzezga, Henning Boecker.   

Abstract

PURPOSE: [(11)C]Flumazenil (FMZ) is a benzodiazepine receptor antagonist that binds reversibly to central-type gamma-aminobutyric acid (GABA-A) sites. A validated approach for analysis of [(11)C]FMZ is the invasive one-tissue (1T) compartmental model. However, it would be advantageous to analyse FMZ binding with whole-brain pixel-based methods that do not require a-priori hypotheses regarding preselected regions. Therefore, in this study we compared invasive and noninvasive data-driven methods (Logan graphical analysis, LGA; multilinear reference tissue model, MRTM2; spectral analysis, SA; basis pursuit denoising, BPD) with the 1T model.
METHODS: We focused on two aspects: (1) replacing the arterial input function analyses with a reference tissue method using the pons as the reference tissue, and (2) shortening the scan protocol from 90 min to 60 min. Dynamic PET scans were conducted in seven healthy volunteers with arterial blood sampling. Distribution volume ratios (DVRs) were selected as the common outcome measure.
RESULTS: The SA, LGA with and without arterial input, and MRTM2 agreed best with the 1T model DVR values. The invasive and noninvasive BPD were slightly less well correlated. The full protocol of a 90-min emission data performed better than the 60-min protocol, but the 60-min protocol still delivered useful data, as assessed by the coefficient of variation, and the correlation and bias analyses.
CONCLUSION: This study showed that the SA, LGA and MRTM2 are valid methods for the quantification of benzodiazepine receptor binding with [(11)C]FMZ using an invasive or noninvasive protocol, and therefore have the potential to reduce the invasiveness of the procedure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043703     DOI: 10.1007/s00259-008-0990-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  Spectral analysis of dynamic PET studies.

Authors:  V J Cunningham; T Jones
Journal:  J Cereb Blood Flow Metab       Date:  1993-01       Impact factor: 6.200

2.  Central benzodiazepine receptors in malformations of cortical development: A quantitative study.

Authors:  A Hammers; M J Koepp; M P Richardson; C Labbé; D J Brooks; V J Cunningham; J S Duncan
Journal:  Brain       Date:  2001-08       Impact factor: 13.501

3.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

4.  Evaluation of the reference tissue models for PET and SPECT benzodiazepine binding parameters.

Authors:  Philippe Millet; Christophe Graf; Alfred Buck; Bernard Walder; Vicente Ibáñez
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

5.  Assessment of spatial normalization of PET ligand images using ligand-specific templates.

Authors:  J H Meyer; R N Gunn; R Myers; P M Grasby
Journal:  Neuroimage       Date:  1999-05       Impact factor: 6.556

6.  Regional hippocampal [11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosis.

Authors:  M J Koepp; C Labbé; M P Richardson; D J Brooks; W Van Paesschen; V J Cunningham; J S Duncan
Journal:  Brain       Date:  1997-10       Impact factor: 13.501

7.  Comparison of plasma input and reference tissue models for analysing [(11)C]flumazenil studies.

Authors:  Ursula M H Klumpers; Dick J Veltman; Ronald Boellaard; Emile F Comans; Cassandra Zuketto; Maqsood Yaqub; Jurgen E M Mourik; Mark Lubberink; Witte J G Hoogendijk; Adriaan A Lammertsma
Journal:  J Cereb Blood Flow Metab       Date:  2007-10-10       Impact factor: 6.200

8.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography.

Authors:  M Maziere; P Hantraye; C Prenant; J Sastre; D Comar
Journal:  Int J Appl Radiat Isot       Date:  1984-10

9.  Differentiation of radioligand delivery and binding in the brain: validation of a two-compartment model for [11C]flumazenil.

Authors:  V A Holthoff; R A Koeppe; K A Frey; A H Paradise; D E Kuhl
Journal:  J Cereb Blood Flow Metab       Date:  1991-09       Impact factor: 6.200

10.  Quantification of benzodiazepine receptors in human brain using PET, [11C]flumazenil, and a single-experiment protocol.

Authors:  J Delforge; S Pappata; P Millet; Y Samson; B Bendriem; A Jobert; C Crouzel; A Syrota
Journal:  J Cereb Blood Flow Metab       Date:  1995-03       Impact factor: 6.200

View more
  8 in total

Review 1.  Imaging the role of GABA in movement disorders.

Authors:  Henning Boecker
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

2.  GABAA Receptors in the Mongolian Gerbil: a PET Study Using [18F]Flumazenil to Determine Receptor Binding in Young and Old Animals.

Authors:  M Kessler; M Mamach; R Beutelmann; M Lukacevic; S Eilert; P Bascuñana; A Fasel; F M Bengel; J P Bankstahl; T L Ross; G M Klump; G Berding
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

3.  In vivo Illustration of Altered Dopaminergic and GABAergic Systems in Early Parkinson's Disease.

Authors:  Hirotsugu Takashima; Tatsuhiro Terada; Tomoyasu Bunai; Takashi Matsudaira; Tomokazu Obi; Yasuomi Ouchi
Journal:  Front Neurol       Date:  2022-05-17       Impact factor: 4.086

Review 4.  [Gastroenteropancreatic neuroendocrine neoplasms. Role of biopsies].

Authors:  F Bergmann
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 5.  Spectral Analysis of Dynamic PET Studies: A Review of 20 Years of Method Developments and Applications.

Authors:  Mattia Veronese; Gaia Rizzo; Alessandra Bertoldo; Federico E Turkheimer
Journal:  Comput Math Methods Med       Date:  2016-12-05       Impact factor: 2.238

6.  Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain.

Authors:  Isadora Lopes Alves; David Vállez García; Andrea Parente; Janine Doorduin; Rudi Dierckx; Ana Maria Marques da Silva; Michel Koole; Antoon Willemsen; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2017-02-22       Impact factor: 3.138

7.  In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy.

Authors:  Lucy Vivash; Marie-Claude Gregoire; Viviane Bouilleret; Alexis Berard; Catriona Wimberley; David Binns; Peter Roselt; Andrew Katsifis; Damian E Myers; Rodney J Hicks; Terence J O'Brien; Stefanie Dedeurwaerdere
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

8.  Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study.

Authors:  Ling Feng; Claus Svarer; Karine Madsen; Morten Ziebell; Agnete Dyssegaard; Anders Ettrup; Hanne Demant Hansen; Szabolcs Lehel; Stig Yndgaard; Olaf Bjarne Paulson; Gitte Moos Knudsen; Lars Hageman Pinborg
Journal:  Biomed Res Int       Date:  2016-03-31       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.